News
Q1 2025 Earnings Call Transcript May 8, 2025 DoubleVerify Holdings, Inc. misses on earnings expectations. Reported EPS is ...
In addition, we've announced the launch of DV's pre-screen brand safety and suitability solution for Google's Search Partner Network or SPN. This launch gives advertisers additional control when ...
The London Company, an investment management company, released “The London Company Small Cap Strategy” first quarter 2025 ...
4h
ThePrint on MSNVoltas mascot Murthy never clicked. His broken Hindi isn’t cute anymoreMurthy returned to Voltas ads after six years to promote Voltas’ new line of SmartAir ACs, with the campaign, ‘Shor Kam, Kaam ...
Hedge your bets and cover your nutritional bases with the best multivitamin of 2025, tested and reviewed by a registered dietitian.
On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical ...
1d
Extra.ie on MSNHMV returns to Munster for first time in more than 10 yearsHMV's second Irish store opens today (Friday, May 16) in a Limerick shopping centre with the first 50 customers receiving a goodie bag!
As connected TV becomes a media mainstay, marketers face a sharp paradox—rising ROI hopes, but murky metrics and mounting ...
Everton's decision to move its men's team out of Goodison Park could be a catalyst for vital change, but there are cautionary ...
On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name ...
YANTAI, China, May 12, 2025 /PRNewswire/ — On May 12th, 2025, RemeGen Co., Ltd. (“RemeGen”, stock symbols: 688331.SH/09995.HK) announced that its phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results